Nyxol Eye Drops + Low-Dose Pilocarpine Eye Drops for Presbyopia
(VEGA-2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing Nyxol alone and with low dose pilocarpine to help people with presbyopia see better up close. The medications work by helping the eye focus better on nearby objects.
Will I have to stop taking my current medications?
You will need to stop using any topical eye medications, except for certain over-the-counter products, at least 7 days before the trial and during the study. If you are taking any systemic adrenergic or cholinergic drugs, you should not change your dosage or start new ones within 7 days before the trial or during the study.
Is the combination of Nyxol Eye Drops and Low-Dose Pilocarpine Eye Drops safe for humans?
How is the drug Nyxol Eye Drops + Low-Dose Pilocarpine Eye Drops for Presbyopia different from other treatments?
This treatment combines Nyxol (phentolamine ophthalmic solution) and low-dose pilocarpine, which together help improve near vision by reducing pupil size and enhancing focus. Unlike other treatments, this combination leverages the unique effects of phentolamine on pupil modulation and pilocarpine's ability to constrict the pupil, offering a novel approach to managing presbyopia.12356
What data supports the effectiveness of the drug Nyxol Eye Drops + Low-Dose Pilocarpine Eye Drops for Presbyopia?
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Nyxol alone or with adjunctive low dose pilocarpine to improve distance-corrected near visual acuity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Low dose pilocarpine
- Low dose pilocarpine vehicle
- Phentolamine Ophthalmic Solution 0.75%
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ocuphire Pharma, Inc.
Lead Sponsor